← All organizations
Highest phase reached
Phase 4
First clinical trial
May 1, 2008Last known activity
Sep 23, 2025
Timeline
2000s
- Jun 1, 2002
Lee's Pharmaceutical— Founded
Drugs by trial phase (63 distinct, 72 trials)
Phase 4 (10 own, 0 via acquisition)
Phase 3 (27 own, 0 via acquisition)
Phase 2 (12 own, 0 via acquisition)
Phase 1 (8 own, 0 via acquisition)
Other trials (6 own, 0 via acquisition)
Indications
Studied for
- Acne Vulgaris
- Acute Pain
- Anemia, Iron-Deficiency
- Biliary Tract Neoplasms
- Bipolar Disorder
- Blood Coagulation Disorders
- Bronchitis
- Bronchitis, Chronic
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Ovarian Epithelial
- Carcinoma, Transitional Cell
- Communicable Diseases
- Coronary Artery Disease
- Coronary Disease
- Depression
- Depressive Disorder
- Dry Eye Syndromes
- Esophageal Neoplasms
- Fallopian Tube Neoplasms
- Glaucoma
- Glaucoma, Open-Angle
- Glioma
- Heart Diseases
- Heart Failure
- Hemoptysis
- Hemostatic Disorders
- Hypertension
- Infarction
- Infections
- Keratoconjunctivitis Sicca
- Lung Neoplasms
- Macular Degeneration
- Myocardial Infarction
- Myocardial Ischemia
- Ocular Hypertension
- Osteosarcoma
- Otitis
- Otitis Externa
- Otitis Media
- Otitis Media, Suppurative
- Pancreatic Neoplasms
- Papillomavirus Infections
- Peripheral Arterial Disease
- Peripheral Nervous System Diseases
- Peripheral Vascular Diseases
- Peritoneal Neoplasms
- Psychomotor Agitation
- Purpura
- Purpura, Thrombocytopenic
- Purpura, Thrombotic Thrombocytopenic
- Renal Artery Obstruction
- Schizophrenia
- Small Cell Lung Carcinoma
- ST Elevation Myocardial Infarction
- Suppuration
- Urinary Bladder, Overactive
- Urinary Tract Infections
- Uterine Cervical Neoplasms
Recent trials (50)
- NCT06953453Lead sponsorPhase 1Sep 23, 2025
- NCT06459687Lead sponsorPhase 3Sep 1, 2024
- NCT06374485Lead sponsorPhase 1Apr 12, 2024
- NCT06160492Lead sponsorPhase 3Feb 29, 2024
- NCT05806918Lead sponsorPhase 3Apr 1, 2023
- NCT06114953Lead sponsorPhase 4Jan 1, 2023
- NCT05531422Lead sponsorPhase 2Sep 20, 2022
- NCT05293704Lead sponsorPhase 4May 1, 2022
- NCT05249725Lead sponsorPhase 4Apr 30, 2022
- NCT04849260Lead sponsorPhase 1/Phase 2Aug 26, 2021
- NCT04982692Lead sponsorPhase 3Jul 31, 2021
- NCT04982692Overall official - principal investigatorPhase 3Jul 31, 2021
- NCT04878016Lead sponsorPhase 3Jul 15, 2021
- NCT04846842Lead sponsorPhase 2Jul 1, 2021
- NCT04713189Lead sponsorPhase 1/Phase 2Mar 15, 2021
Details
- Founded
- Hong Kong, HK Jun 1, 2002
- Last known activity
- Sep 23, 2025